Ins and Outs Modulating Hepatic Triglyceride and Development of Nonalcoholic Fatty Liver Disease

Gastroenterology

Volumn 130, Issue 4, 2006, Pages 1343-1346

  Goldberg, Ira J ^a   Ginsberg, Henry N ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; TRIACYLGLYCEROL;

ARTICLE; FATTY ACID TRANSPORT; FATTY LIVER; GENE EXPRESSION; HOMEOSTASIS; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID TRANSPORT; NONALCOHOLIC FATTY LIVER; OXIDATION; PRIORITY JOURNAL;

EID: 33645978418     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.02.040     Document Type: Article

References (24)

1. Evans K., Burdge G.C., Wootton S.A., Clark M.L., and Frayn K.N. Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes 51 (2002) 2684-2690
2. Hamilton J.A., and Kamp F. How are free fatty acids transported in membranes?. Is it by proteins or by free diffusion through the lipids?. Diabetes 48 (1999) 2255-2269
3. Hajri T., and Abumrad N.A. Fatty acid transport across membranes. relevance to nutrition and metabolic pathology. Annu Rev Nutr 22 (2002) 383-415
4. Moitra J., Mason M.M., Olive M., Krylov D., Gavrilova O., Marcus-Samuels B., Feigenbaum L., Lee E., Aoyama T., Eckhaus M., Reitman M.L., and Vinson C. Life without white fat. a transgenic mouse. Genes Dev 12 (1998) 3168-3181
5. Hajri T., Han X.X., Bonen A., and Abumrad N.A. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest 109 (2002) 1381-1389
6. Miyazaki M., Dobrzyn A., Sampath H., Lee S.H., Man W.C., Chu K., Peters J.M., Gonzalez F.J., and Ntambi J.M. Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha. J Biol Chem 279 (2004) 35017-35024
7. Merkel M., Weinstock P.H., Chajek-Shaul T., Radner H., Yin B., Breslow J.L., and Goldberg I.J. Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia. J Clin Invest 102 (1998) 893-901
8. Hellerstein M.K. De novo lipogenesis in humans. metabolic and regulatory aspects. Eur J Clin Nutr 53 Suppl 1 (1999) S53-S65
9. Matsusue K., Haluzik M., Lambert G., Yim S.H., Gavrilova O., Ward J.M., Brewer Jr. B., Reitman M.L., and Gonzalez F.J. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111 (2003) 737-747
10. Yu S., Matsusue K., Kashireddy P., Cao W.Q., Yeldandi V., Yeldandi A.V., Rao M.S., Gonzalez F.J., and Reddy J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 278 (2003) 498-505
11. Rao M.S., and Reddy J.K. PPARalpha in the pathogenesis of fatty liver disease. Hepatology 40 (2004) 783-786
12. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisler JG, Bhanot S, Monia BP, Shulman GI. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006;(Feb 16 Epub ahead of print).
13. Fisher E.A., and Ginsberg H.N. Complexity in the secretory pathway. the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 277 (2002) 17377-17380
14. Zhang Y.L., Hernandez-Ono A., Ko C., Yasunaga K., Huang L.S., and Ginsberg H.N. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem 279 (2004) 19362-19374
15. Chakravarthy M.V., Pan Z., Zhu Y., Tordjman K., Schneider J.G., Coleman T., Turk J., and Semenkovich C.F. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 1 (2005) 309-322
16. Schonfeld G. Familial hypobetalipoproteinemia. a review. J Lipid Res 44 (2003) 878-883
17. Raabe M., Flynn L.M., Zlot C.H., Wong J.S., Veniant M.M., Hamilton R.L., and Young S.G. Knockout of the abetalipoproteinemia gene in mice. reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc Natl Acad Sci U S A 95 (1998) 8686-8691
18. Vance J.E., and Vance D.E. Metabolic insights into phospholipid function using gene-targeted mice. J Biol Chem 280 (2005) 10877-10880
19. den Boer M., Voshol P.J., Kuipers F., Havekes L.M., and Romijn J.A. Hepatic steatosis: a mediator of the metabolic syndrome: Lessons from animal models. Arterioscler Thromb Vasc Biol 24 (2004) 644-649
20. Stiles B., Wang Y., Stahl A., Bassilian S., Lee W.P., Kim Y.J., Sherwin R., Devaskar S., Lesche R., Magnuson M.A., and Wu H. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. [corrected]. Proc Natl Acad Sci U S A 101 (2004) 2082-2087
21. Ono H., Shimano H., Katagiri H., Yahagi N., Sakoda H., Onishi Y., Anai M., Ogihara T., Fujishiro M., Viana A.Y., Fukushima Y., Abe M., Shojima N., Kikuchi M., Yamada N., Oka Y., and Asano T. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52 (2003) 2905-2913
22. Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., and Kahn C.R. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6 (2000) 87-97
23. Nanji A.A. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin Liver Dis 8 (2004) 559-574
24. Jump D.B. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 13 (2002) 155-164